CHICAGO, April 7, 2008 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. , today announced that it will host a conference call and live webcast at 8:30 am (EDT) on Thursday, April 10, 2008. The focus of the call will be to discuss the Company’s April 7, 2008 meeting with The US Food & Drug Administration (FDA) on the planned NDA submission for the Company’s novel once-a-day oral antibiotic, cethromycin, as a treatment for mild-to-moderate Community Acquired Pneumonia (CAP).
Conference Call Details:
The conference call will be webcast simultaneously over the Internet. Please visit the Investor Relations section of the Advanced Life Sciences corporate website www.advancedlifesciences.com. Alternatively, callers may participate in the conference call by dialing 888-680-0894(domestic) or 617-213-4860(international). The passcode for the conference call is 31431743. A replay of the conference call will be available until April 17, 2008. Callers may access the telephone replay by dialing 888-286-8010 (domestic) or 617-801-6888 (international), passcode 33735345. Investors are advised to dial into the call at least ten minutes prior to the call to register. Participants may pre-register for the call at https://www.theconferencingservice.com/prereg/key.process?key=PXKLGN4DD. Pre-registrants will be issued a pin number to use when dialing into the live call which will provide quick access to the conference by bypassing the operator upon connection.
About Advanced Life Sciences
Advanced Life Sciences is a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and respiratory diseases. The Company’s lead candidate, cethromycin, is a novel once-a-day oral antibiotic in late-stage development for the treatment of respiratory tract infections including CAP. For more information, please visit us on the web at www.advancedlifesciences.com.
Forward-Looking Statements
Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements represent our management’s judgment regarding future events. The Company does not undertake any obligations to update any forward-looking statements whether as a result of new information, future events or otherwise. Our actual results could differ materially from those discussed herein due to several factors including the success and timing of a commercial partnership and our ability to obtain and maintain regulatory approval and labeling of our product candidates; our plans to develop and commercialize our product candidates; the loss of key scientific or management personnel; the size and growth of potential markets for our product candidates and our ability to serve those markets; regulatory developments in the U.S. and foreign countries; the rate and degree of market acceptance of any future products; the accuracy of our estimates regarding expenses, future revenues and capital requirements; our ability to obtain financing on terms acceptable to us; our ability to obtain and maintain intellectual property protection for our product candidates; the successful development of our sales and marketing capabilities; the success of competing drugs that become available; and the performance of third party collaborators and manufacturers. These and additional risks and uncertainties are detailed in the Company’s filings with the Securities and Exchange Commission.
CONTACT: Company Contact: Joe Camp of Advanced Life Sciences Holdings,
Inc., +1-630-754-4352, jcamp@advancedlifesciences.com; Media Contact:
Melanie Nimrodi, Financial Relations Board, +1-312-546-3508,
mnimrodi@frbir.com; Investors Contact: Kathy Price, Financial Relations
Board, +1-213-486-6547, kprice@frbir.com
Web site: http://www.advancedlifesciences.com/
